Ever Supreme Bio Technology saw doubled growth in profits and dividends last year, setting new records with an EPS of $7.24. The board decided to distribute dividends of $7 per share ($6 in cash dividends and $1 in stock dividends). With visibility of orders extending to the fourth quarter and an expansion in the number of collaborating hospitals and cellular therapy projects, Chairman Chu-chi Liu is optimistic about achieving new operational highs this year.
Ever Supreme Bio Technology benefited from revenue growth, financial asset valuation, and a profit of 139 million from investment disposals last year, resulting in an operating profit of 338 million NTD and a net profit after tax of 539 million, an increase of 1.68 times compared to the previous year, with EPS reaching a new high of $7.2. The shareholder meeting is scheduled for April 30.
Chu-chi Liu stated that Ever Supreme Bio Technology adopts a dual-track strategy of new drug development and special management measures, resulting in doubled profits last year. Benefiting from the optimization of cellular contract manufacturing, the gross profit margin reached 60% for the year. Currently, visibility of orders for cellular contract manufacturing extends to the fourth quarter, and the number of collaborating hospitals and cellular therapy projects continues to expand, with expectations of achieving new profit highs this year.
Ever Supreme Bio Technology's new drug, Umbilical Cord Mesenchymal Stem Cell (UMSC01), has entered phase IIa clinical trials for acute myocardial infarction and phase I/IIa clinical trials for multiple sclerosis, with successful enrollment.
Ever Supreme Bio Technology's immune allogeneic CAR-T cell therapy for colorectal cancer, breast cancer, lung cancer, and malignant brain cancer has been approved by the US FDA, initiating phase I/IIa clinical trials for late-stage recurrent and refractory solid tumors. An application for new drug clinical trials has also been submitted to the Taiwan FDA.
Resource (Mandarin): 長聖 去年獲利成長翻倍
